- Home
- RNA vs OTLK Comparison
RNA vs OTLK Comparison
Compare RNA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | OTLK |
|---|---|---|
| Founded | 2025 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.5M | 249.6M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RNA | OTLK |
|---|---|---|
| Price | $7.94 | $0.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $25.00 | $5.03 |
| AVG Volume (30 Days) | 419.4K | ★ 3.4M |
| Earning Date | 08-13-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | $84.55 | N/A |
| Revenue Next Year | N/A | $6,355.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.63 | $0.16 |
| 52 Week High | $73.06 | $2.54 |
Technical Indicators
Market Signals| Indicator | RNA | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 24.73 | 33.30 |
| Support Level | N/A | $0.50 |
| Resistance Level | $14.05 | $0.72 |
| Average True Range (ATR) | 0.46 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 12.10 | 20.03 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.